4598.T) reported positive results from its phase 1/2 clinical trial combining DFP-101 with">
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from Delta-Fly Pharma,Inc. was processed by Pulse News Wire on March 25, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Mar 25 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) reported positive results from its phase 1/2 clinical trial combining DFP-101 with venetoclax for relapsed/refractory acute myeloid leu